This trial will help researchers understand how the antiviral drug Tenofovir alafenamide helps to reduce liver inflammation in patients with chronic hepatitis B.
- Chronic Hepatitis B
3 Primary · 0 Secondary · Reporting Duration: 3 years
Awards & Highlights
0 Treatment Group
15 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · Phase 4
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any antecedent investigations into this therapeutic approach?
"Presently, 73 studies investigate this therapeutic intervention. Of which, 16 are in Phase 3 of their trials. Primarily situated near Myslowice, Maryland; 1430 locations facilitate research related to this treatment regimen." - Anonymous Online Contributor
What safety assessments have been made to ensure this treatment is secure for individuals?
"As this is a Phase 4 trial, with an approved treatment protocol and existing data supporting safety, it was assigned the highest rating of 3." - Anonymous Online Contributor
How many human participants are being evaluated in this clinical research?
"Verified. Reports from clinicaltrials.gov demonstrate that this particular trial is actively recruiting patients, having first been posted on 29th January 2019 and last updated 23rd August 2019. It requires 15 participants to be admitted across one site." - Anonymous Online Contributor
Are there openings presently available in this clinical trial?
"Affirmative. Reports on clinicaltrials.gov show that the trial, which was first advertised in January of 2019 is currently seeking participants. In total, 15 patients are sought to be recruited from a single medical site." - Anonymous Online Contributor
What indications is this treatment typically prescribed for?
"This medication is commonly prescribed for people without a prior history of treatment. Furthermore, it may be recommended to those with HIV-1 and weight at least 35 kg who have not developed resistance to darunavir." - Anonymous Online Contributor